Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Biopharmaceutical company Agios Pharmaceuticals Inc filed with U.S. regulators on Monday to raise up to $86 million in an initial public offering of common stock. The Cambridge, Massachusetts-based company told the U.S. Securities and Exchange Commission in a preliminary prospectus that JP Morgan and Goldman Sachs & Co are lead underwriters in the IPO. () Agios said it was working with Celgene Corp on a program focused on cancer metabolism. Celgene, which has a 17 percent stake in Agios, has agreed to purchase an undisclosed amount of Agios stock in a separate private placement at the IPO price.
Help employers find you! Check out all the jobs and post your resume.
Biopharmaceutical company Agios Pharmaceuticals Inc filed with U.S. regulators on Monday to raise up to $86 million in an initial public offering of common stock. The Cambridge, Massachusetts-based company told the U.S. Securities and Exchange Commission in a preliminary prospectus that JP Morgan and Goldman Sachs & Co are lead underwriters in the IPO. () Agios said it was working with Celgene Corp on a program focused on cancer metabolism. Celgene, which has a 17 percent stake in Agios, has agreed to purchase an undisclosed amount of Agios stock in a separate private placement at the IPO price.
Help employers find you! Check out all the jobs and post your resume.
